0
Blueprint Medicines Corp
- 501-1000 Employees
- Based in Cambridge, Massachusetts
Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company’s lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder…More
Blueprint Medicines Corp
Most Recent Responsibility Report
Blueprint Medicines Corp does not currently have any hardcopy reports on ResponsibilityReports.com. Click the button below to request a report when hardcopies become available.
Please fill out the form below and click "Place Order" to complete your order.
Archived Responsibility Reports
Our service enables potential investors to review the most recent and archived Blueprint Medicines Corp Sustainability Report, Blueprint Medicines Corp Corporate Social Responsibility Report, Blueprint Medicines Corp CSR Report, Blueprint Medicines Corp Corporate Responsibility, Blueprint Medicines Corp CR Report, Blueprint Medicines Corp Citizenship Report, Blueprint Medicines Corp ESG Report, and Blueprint Medicines Corp Environmental Report online.